Gastrointestinal Stromal Tumors. Management of Metastatic Disease and Emerging Therapies.

Hematology/Oncology Clinics of North America

Volumn 27, Issue 5, 2013, Pages 905-920

  Vadakara, Joseph ^a   von Mehren, Margaret ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

GIST; HSP90; IGF 1R; KIT; PDGFRA; SDH deficient GIST; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; AT 13387; B RAF KINASE; BIIB 021; CEDIRANIB; CHR 258; CP 868 596; CRENOLANIB; DOVITINIB; EVEROLIMUS; GANETESPIB; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IMC 3G 3; LINSITINIB; LUMINESPIB; MASITINIB; MONOCLONAL ANTIBODY; NILOTINIB; OLARATUMAB; PAZOPANIB; PERIFOSINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RAS PROTEIN; REGORAFENIB; RETASPIMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB;

ADVANCED CANCER; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; EXON; FAINTNESS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; LEUKOPENIA; METASTASIS; MYALGIA; NAUSEA; OVERALL SURVIVAL; PERIORBITAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; WILD TYPE;

GIST; HSP90; IGF-1R; KIT; PDGFRA; SDH-DEFICIENT GIST; TYROSINE KINASE INHIBITORS;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS;

EID: 84884959316     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.07.007     Document Type: Review

References (78)

1. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001, 61:8118-8121.
2. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
3. Miranda C., Nucifora M., Molinari F., et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 2012, 18:1769-1776.
4. Belinsky M.G., Rink L., Flieder D., et al. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer 2013, 52:214-224.
5. Mussi C., Schildhaus H.U., Gronchi A., et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008, 14:4550-4555.
6. Joensuu H., Roberts P.J., Sarloma-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. NEngl J Med 2001, 344:1052-1056.
7. van Oosterom A.T., Judson I., Verwelj J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
8. van Oosterom A.T., Judson I.R., Verwelj J., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38(Suppl 5):S83-S87.
9. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEngl J Med 2002, 347:472-480.
10. Verweij J., van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39:2006-2011.
11. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
12. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. JClin Oncol 2008, 26:626-632.
13. Gastrointestinal Stromal Tumor Meta-Analysis Group Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. JClin Oncol 2010, 28:1247-1253.
14. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. JClin Oncol 2006, 24:4764-4774.
15. Wardelmann E., Thomas N., Merkelbach-Bruse S., et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005, 6:249-251.
16. Debiec-Rychter M., Cools J., Dumez H., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128:270-279.
17. Blanke C.D., Rankin C., Demetri G.D., et al. Long term results from a randomized phase II trial of standard versus higher dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. JClin Oncol 2008, 26:626-632.
18. Faivre S., Demetri G., Sargent W., et al. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745.
19. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. JClin Oncol 2006, 24:25-35.
20. Heinrich M.C., Maki R.G., Corless C.L., et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. JClin Oncol 2008, 26:5352-5359.
21. Heinrich M., Maki R.G., Corless C.R., et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. JClin Oncol 2006, 24(Suppl 18):a9502.
22. Maki R.G., Fletcher J.A., Heinrich M.C., et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2005, 9011.
23. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
24. George S., Blay J.Y., Casali P.G., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009, 45:1959-1968.
25. Wilhelm S.M., Dumas J., Adnane L., et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011, 129:245-255.
26. George S., Wang Q., Heinrich M.C., et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. JClin Oncol 2012, 30:2401-2407.
27. Demetri G.D., Reichardt P., Kang Y.K., et al. Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. J Clin Oncol (ASCO Meeting Abstracts) 2012, 30(Suppl 18):LBA10008.
28. Wilhelm S.M., Adnane L., Newell P., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7:3129-3140.
29. Heinrich M.C., Carden R., Griffith D., et al. Invitro activity of sorafenib against imatinib- and sunitinib-resistant kinase mutations associated with drug-resistant GI stromal tumors. J Clin Oncol (ASCO Meeting Abstracts) 2009, 27(Suppl 15):10500.
30. Reichardt P., Montemurro M., Gelderblom H., et al. Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis. J Clin Oncol (ASCO Meeting Abstracts) 2009, 27(Suppl 15):10564.
31. Kindler H., Campbell N.P., Wroblewski K., et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase II Consortium trial. J Clin Oncol (ASCO Meeting Abstracts) 2011, 29(Suppl 15):10009.
32. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60:2178-2189.
33. Joensuu H., De Braud F., Grignagni G., et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 2011, 104:1686-1690.
34. Lee S.H., Lopes de Menezes D., Vora J., et al. Invivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005, 11:3633-3641.
35. Sarker D., Molife R., Evans T.R., et al. Aphase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008, 14:2075-2081.
36. Kumar R., Knick V.B., Rudolph S.K., et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007, 6:2012-2021.
37. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65:4389-4400.
38. Weisberg E., Manley P.W., Breiltenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
39. Demetri G.D., Casali P.G., Blay J.Y., et al. Aphase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009, 15:5910-5916.
40. Cauchi C., Somaiah N., Engstrom P.F., et al. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 2012, 69:977-982.
41. Sawaki A., Nishida T., Doi T., et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011, 117:4633-4641.
42. Montemurro M., Schöffski P., Reichardt P., et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009, 45:2293-2297.
43. Reichardt P., Blay J.Y., Gelderblom H., et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012, 23:1680-1687.
44. Soria J.C., Massard C., Magné N., et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 2009, 45:2333-2341.
45. Blay J., Le Cesne A., Bin N., et al. Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial. ASCO Meeting Abstracts 2011, 85.
46. Le Cesne A., Blay J.Y., Bui B.N., et al. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010, 46:1344-1351.
47. Adenis A., Le Cesne A., Nguyen B.B., et al. Masitinib mesylate in imatinib-resistant advanced GIST: a randomized phase II trial. ASCO Meeting Abstracts 2012, 30(Suppl 15):10007.
48. Bauer S., Yu L.K., Demetri G.D., et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006, 66:9153-9161.
49. Demetri GD, Le Cesne A, von Mehren M, etal. Final results from a phase III study of IPI-504 (retsapimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. In: ASCO Gastrointestinal Cancers Symposium. Orlando, FL; January 22-24, 2010. [abstract 64].
50. Muhlenberg T., Zhang Y., Wagner A.J., et al. Inhibitors of deacetylases suppress oncogenic KIT signalling, acetylate HSP90, and induce apopotosis in gastrointestinal stromal tumors. Cancer Res 2009, 69:6941-6950.
51. Lundgren K., Zhang H., Brekken J., et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009, 8:921-929.
52. Dickson M.A., Okuno S.H., Keohan M.L., et al. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol 2013, 24:252-257.
53. Smyth T., Van Looy T., Curry J.E., et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther 2012, 11:1799-1808.
54. Hsueh Y.S., Yen C.C., Shih N.Y., et al. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors. Autophagy 2013, 9:220-233.
55. Samuel T., Sessa C., Britten C., et al. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. JClin Oncol 2010, 28(Suppl 15):2528.
56. Fletcher J., Debiec-Rychter M., Swank S., et al. HSP90 inhibitor STA-9090 potently suppresses heterogeneous KIT kinase-domain mutations responsible for gastrointestinal stromal tumor progression during imatinib therapy. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Mol Cancer Ther 2009, 8(Suppl 12):B184.
57. Demetri G., Heinrich M.C., Chmielowski B., et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. ASCO Meeting Abstracts 2011, 10011.
58. Bauer S., Duensing A., Demetri G.D., et al. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 2007, 26:7560-7568.
59. Rossi F., Ehlers I., Agosti V., et al. Oncogenic KITsignaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 2006, 103:12843-12848.
60. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003, 2:1093-1103.
61. Conley A., Araujo D., Ludwig J., et al. Arandomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts) 2009, 27(Suppl 15):10563.
62. Schöffski P., Reichardt P., Blay J.Y., et al. Aphase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010, 21:1990-1998.
63. Hohenberger P., Bauer S., Gruenwald V., et al. Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST. JClin Oncol 2010, 28:10048. ASCO Meeting Abstracts.
64. Palassini E., Fumagalli E., Coco P., et al. Combination of PKC412 and sirolimus in a metastatic patient with PDGFRA-D842V gastrointestinal stromal tumor (GIST). JClin Oncol 2008, 21515. ASCO Meeting Abstracts.
65. Piovesan C., Fumagalli E., Coco P., et al. Response to sirolimus in combination totirosine kinase inhibitors (TKI) in three cases of PDGFRA-D842V metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Meeting Abstracts) 2009, 27(Suppl 15):10565.
66. Heinrich M.C., Griffith D., McKinley A., et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2012, 18:4375-4384.
67. Lewis N.L., Lewis L.D., Eder J.P., et al. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. JClin Oncol 2009, 27:5262-5269.
68. Wagner A.J., Remillard S.P., Zhang Y.X., et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol 2013, 26:289-294.
69. Italiano A., Chen C.L., Sung Y.S., et al. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. BMC Cancer 2012, 12:408.
70. Oudijk L., Gaal J., Korpershoek E., et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod Pathol 2013, 26:456-463.
71. Dwight T., Benn D.E., Clarkson A., et al. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol 2013, 37:226-233.
72. Miettinen M., Killian J.K., Wang Z.F., et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol 2013, 37:234-240.
73. Carney J.A., Stratakis C.A. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 2002, 108:132-139.
74. Pantaleo M.A., Nannini M., Astolfi A., et al. Adistinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations. Am J Surg Pathol 2011, 35:1750.
75. Tarn C., Rink L., Merkel E., et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008, 105:8387-8392.
76. Miettinen M., Wang Z.F., Sarlomo-Rikala M., et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol 2011, 35:1712-1721.
77. Cervera A.M., Apostolova N., Crespo F.L., et al. Cells silenced for SDHB expression display characteristic features of the tumor phenotype. Cancer Res 2008, 68:4058-4067.
78. Larsson O., Girnita A., Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2005, 92:2097-2101.